Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
empagliflozin + metformin
- Development stage
- Approved
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Empagliflozin + metformin is a fixed-dose oral combination of two antidiabetic agents used to treat type 2 diabetes mellitus. Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that works by preventing glucose reabsorption in the kidneys, thereby increasing urinary glucose excretion and lowering blood sugar levels. Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity. This combination not only improves glycemic control but also reduces the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease. It is also indicated to lower the risk of hospitalization for heart failure and progression of chronic kidney disease in appropriate patient populations[1][4][5][6].
- Brand names
- SynjardySynjardy XRJardiamet
- Other names
- empagliflozin/metforminempagliflozin and metformin
02
Targets
GPD2 (Glycerol-3-phosphate dehydrogenase 2)SGLT2 (Sodium-glucose cotransporter protein subunit 2)ND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on empagliflozin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on empagliflozin + metformin.